KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Recursion Pharmaceuticals (RXRX) Goodwill (2020 - 2025)

Historic Goodwill for Recursion Pharmaceuticals (RXRX) over the last 6 years, with Q3 2025 value amounting to $162.0 million.

  • Recursion Pharmaceuticals' Goodwill rose 21128.4% to $162.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $162.0 million, marking a year-over-year increase of 21128.4%. This contributed to the annual value of $148.9 million for FY2024, which is 18598.62% up from last year.
  • Latest data reveals that Recursion Pharmaceuticals reported Goodwill of $162.0 million as of Q3 2025, which was up 21128.4% from $164.3 million recorded in Q2 2025.
  • In the past 5 years, Recursion Pharmaceuticals' Goodwill registered a high of $164.3 million during Q2 2025, and its lowest value of $801000.0 during Q1 2021.
  • In the last 5 years, Recursion Pharmaceuticals' Goodwill had a median value of $52.1 million in 2023 and averaged $50.6 million.
  • As far as peak fluctuations go, Recursion Pharmaceuticals' Goodwill surged by 745505.62% in 2023, and later plummeted by 1397.98% in 2024.
  • Over the past 5 years, Recursion Pharmaceuticals' Goodwill (Quarter) stood at $801000.0 in 2021, then changed by 0.0% to $801000.0 in 2022, then skyrocketed by 6398.88% to $52.1 million in 2023, then skyrocketed by 185.99% to $148.9 million in 2024, then increased by 8.85% to $162.0 million in 2025.
  • Its Goodwill stands at $162.0 million for Q3 2025, versus $164.3 million for Q2 2025 and $158.1 million for Q1 2025.